Loading
NFKBIA (NF-kappa-B inhibitor alpha) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma and Diffuse large B-cell lymphoma.
Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL (RELA/p65 and NFKB1/p50) dimers in the cytoplasm by masking their nuclear localisation signals. On cellular stimulation by immune and pro-inflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate to the nucleus and activate transcription.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 5 cohorts (0 activating, 5 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma, Plasma Cell Myeloma.
In plain words · NFKBIA (NF-kappa-B inhibitor alpha) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma and Diffuse large B-cell lymphoma.
NFKBIA (NF-kappa-B inhibitor alpha) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma and Diffuse large B-cell lymphoma.
Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL (RELA/p65 and NFKB1/p50) dimers in the cytoplasm by masking their nuclear localisation signals.
No product in this corpus aims at NFKBIA yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA NFKBIA: RNA tissue enhanced (bone marrow 961 nTPM); no normal tissue stained high; highest cancer staining prostate cancer (1 of 8 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Multiple myeloma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P25963; CIViC gene NFKBIA; IntOGen NFKBIA; Human Protein Atlas NFKBIA tissue; Open Targets ENSG00000100906 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Haskill et al, Cell, 1991, "Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity". Source.
Sources: HGNC HGNC:7797 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P25963 (protein name, function text, keywords and locations (REST API)); CIViC gene NFKBIA (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); IntOGen NFKBIA (driver in 5 cohorts (Act 0, LoF 5); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL (RELA/p65 and NFKB1/p50) dimers in the cytoplasm by masking their nuclear localisation signals. On cellular stimulation by immune and pro-inflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate to the nucleus and activate transcription. Location: Cytoplasm; Nucleus (UniProt). Locus 14q13.2 (HGNC).
RNA: tissue enhanced (bone marrow 961 nTPM), detected in all normal tissues.
No normal tissue stained high; medium in Adrenal gland, Appendix, Bone marrow, Breast, Bronchus, Caudate and more.
Medium only: breast cancer, carcinoid, cervical cancer, colorectal cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"NFKBIA" OR ABSTRACT:"NFKBIA" OR TITLE:"NFKB inhibitor alpha" OR ABSTRACT:"NFKB inhibitor alpha" OR TITLE:"NF-kappa-B inhibitor alpha" OR ABSTRACT:"NF-kappa-B inhibitor alpha" OR TITLE:"MAD-3" OR ABSTRACT:"MAD-3" OR TITLE:"IkappaBalpha" OR ABSTRACT:"IkappaBalpha" OR TITLE:"NFKBI" OR ABSTRACT:"NFKBI") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NFKBIA, not a curated reading list.